QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)

biote (BTMD) Stock Price, News & Analysis

$5.44
-0.08 (-1.45%)
(As of 04:00 PM ET)
Today's Range
$5.30
$5.62
50-Day Range
$3.97
$6.91
52-Week Range
$3.65
$8.22
Volume
69,885 shs
Average Volume
110,962 shs
Market Capitalization
$405.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.11

biote MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
49.1% Upside
$8.11 Price Target
Short Interest
Bearish
2.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
53.85%
From $0.39 to $0.60 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.60 out of 5 stars

Medical Sector

439th out of 919 stocks

Medicinals & Botanicals Industry

3rd out of 9 stocks

BTMD stock logo

About biote Stock (NASDAQ:BTMD)

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

BTMD Stock Price History

BTMD Stock News Headlines

Your Next Portfolio Star: Revealing 2024's Top Stock Pick
We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
This company has increased its dividend every year for 54 years
There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.
Preview: Biote's Earnings
Birmingham manufacturer to be acquired for $8.5M
Biote price target lowered by $1 at Truist, here's why
Biote names Robert Peterson as its CFO
Biote Names Robert Peterson CFO
Biote Names Robert Peterson as Chief Financial Officer
biote Should Keep Delivering Strong Growth
BIOTE GAAP EPS of $0.24, revenue of $45.6M
Biote Reports Third Quarter 2023 Financial Results
See More Headlines
Receive BTMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for biote and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/12/2024
Today
4/18/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medicinals & botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:BTMD
Employees
194
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.11
High Stock Price Target
$9.00
Low Stock Price Target
$6.55
Potential Upside/Downside
+49.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$3.32 million
Pretax Margin
-0.07%

Debt

Sales & Book Value

Annual Sales
$185.36 million
Cash Flow
$0.47 per share
Book Value
($0.58) per share

Miscellaneous

Free Float
62,160,000
Market Cap
$404.70 million
Optionable
Not Optionable
Beta
0.87
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

BTMD Stock Analysis - Frequently Asked Questions

Should I buy or sell biote stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for biote in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BTMD shares.
View BTMD analyst ratings
or view top-rated stocks.

What is biote's stock price target for 2024?

5 brokers have issued 12 month target prices for biote's shares. Their BTMD share price targets range from $6.55 to $9.00. On average, they expect the company's stock price to reach $8.11 in the next year. This suggests a possible upside of 49.1% from the stock's current price.
View analysts price targets for BTMD
or view top-rated stocks among Wall Street analysts.

How have BTMD shares performed in 2024?

biote's stock was trading at $4.94 at the beginning of 2024. Since then, BTMD stock has increased by 10.1% and is now trading at $5.44.
View the best growth stocks for 2024 here
.

Are investors shorting biote?

biote saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 878,200 shares, an increase of 16.4% from the March 15th total of 754,400 shares. Based on an average daily volume of 117,500 shares, the short-interest ratio is currently 7.5 days. Approximately 2.6% of the company's shares are short sold.
View biote's Short Interest
.

When is biote's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our BTMD earnings forecast
.

How were biote's earnings last quarter?

biote Corp. (NASDAQ:BTMD) posted its quarterly earnings data on Tuesday, March, 12th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.06. The firm earned $45.70 million during the quarter, compared to the consensus estimate of $45.50 million. biote had a net margin of 1.79% and a negative trailing twelve-month return on equity of 45.10%.

What guidance has biote issued on next quarter's earnings?

biote updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $200.0 million-$204.0 million, compared to the consensus revenue estimate of $203.2 million.

How do I buy shares of biote?

Shares of BTMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BTMD) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners